GlassScriptPhysician profile
Edward L Middleman
NPI 1972540623
$369.67
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.53 · 2020: $185 · 2022: $146.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $71.05 | 2020 | |
| Amgen INC. | $56.57 | 2020-2022 | |
| Sirtex Medical INC | $32.28 | 2022 | |
| Myovant Sciences INC. | $29.29 | 2022 | |
| Deciphera Pharmaceuticals INC. | $24.38 | 2022 | |
| Genzyme Corporation | $23.61 | 2020 | |
| Incyte Corporation | $22.92 | 2020 | |
| Jazz Pharmaceuticals INC. | $22.29 | 2022 | |
| Puma Biotechnology, INC. | $20.17 | 2020 | |
| Lilly USA, LLC | $14.62 | 2020 | |
| Seagen INC. | $14.02 | 2019 | |
| Servier Pharmaceuticals LLC | $13.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.46 | 2019 | |
| Daiichi Sankyo INC. | $11.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Middleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.